R Squared’s Kyverna Therapeutics KYTX Stock Holding History

R Squared’s Portfolio KYTX Stock Details KYTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-240	Closed	-$898	–	1551
2024 Q4	$898	Buy	+240	New	+$1.15K	﹤0.01%	1519

Other funds holding KYTX

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

IHG

Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

MPM

MBB Public Markets Chicago, Illinois $839M AUM 20.48% 1-Year Est. Return

R Squared's KYTX Position: Q1 2025 in Review

R Squared sold out of Kyverna Therapeutics (KYTX) in Q1 2025, closing a stake of 240 shares — an estimated $898 sold.

R Squared first reported a position in KYTX in Q4 2024 and held it in 1 quarter. The position peaked at $898 in Q4 2024. 87 funds tracked by Wall St. Rank hold KYTX as of Q1 2025.

R Squared reported no remaining Kyverna Therapeutics position as of Q1 2025 after selling out during the quarter.
R Squared sold 240 Kyverna Therapeutics shares in Q1 2025, an estimated $898.
R Squared first reported a position in Kyverna Therapeutics in Q4 2024 and held it in 1 quarter.
R Squared's Kyverna Therapeutics position peaked at $898 in Q4 2024.
87 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.